Introduction {#Sec1}
============

Observational and experimental data support an independent, positive relationship between sodium intake and blood pressure, most clearly in hypertensive populations \[[@CR1]--[@CR3]\]. Potassium intake, on the other hand, has been inversely related to blood pressure \[[@CR3], [@CR4]\]. Since hypertension is a strong predictor of cardiovascular disease (CVD), especially stroke, inadequate intake of sodium and potassium is likely to be associated with increased cardiovascular morbidity and mortality \[[@CR1]\]. Only recently, population-based studies on dietary salt intake in relation to CVD and non-cardiovascular events have received priority \[[@CR5]\]. Alderman et al. were among the first to report an increased risk of myocardial infarction with low urinary sodium in treated hypertensive men \[[@CR6]\]. In a subsequent analysis of NHANES I data, an inverse association of sodium intake with all-cause and cardiovascular mortality was found \[[@CR7]\]. Estimation of salt intake by 24-h dietary recall and other methodological aspects of this analysis, however, have been criticized \[[@CR8]--[@CR10]\]. Salt intake was not significantly related to coronary or all-cause mortality in the large cohorts of the Scottish Heart Health Study \[[@CR11]\] and the MRFIT trial \[[@CR12]\]. A recent systematic review of 11 randomized trials showed no effect of long-term sodium reduction on overall mortality, but this meta-analysis included only 17 fatal events and should be interpreted with caution \[[@CR13]\]. He et al. showed that high sodium intake was a strong risk factor for congestive heart failure in overweight participants of the NHANES I follow-up study \[[@CR14]\], and also predictive for CVD and all-cause mortality in this group \[[@CR15]\]. Similarly, in a Finnish cohort, 24-h urinary sodium excretion predicted mortality and risk of coronary heart disease only in the presence of overweight \[[@CR16]\]. With regard to incidence of stroke, the Finnish study showed no association with urinary sodium \[[@CR16]\]. Stroke mortality was neither predicted by dietary sodium intake in MRFIT \[[@CR12]\]. In the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study in 24 countries, however, sodium intake appeared to be a risk factor for stroke in men \[[@CR17]\]. As a consequence of these inconsistent findings, there is currently no consensus as to the cardiovascular risks of salt intake.

Tobian et al. demonstrated a lower risk of hemorrhagic stroke and mortality in hypertensive rats that had been given potassium supplements, an effect that was not mediated by blood pressure reduction \[[@CR18]\]. Khaw and Barrett-Connor confirmed this independent protective effect of dietary potassium against stroke in humans \[[@CR19]\]. Also in the CARDIAC study \[[@CR17]\], the Cardiovascular Health Study \[[@CR20]\] and the Nurses Health Study \[[@CR21]\] the intake of potassium was inversely related to risk of stroke. Data on dietary potassium in relation to coronary and all-cause mortality in humans are scanty. We examined the relationship of sodium and potassium intake with cardiovascular events and all-cause mortality in the older cohort of the population-based Rotterdam Study.

Methods {#Sec2}
=======

The Rotterdam Study {#Sec3}
-------------------

This case--cohort analysis formed part of the Rotterdam Study, a population-based prospective study among 7,983 men and women aged 55 years and older in the Netherlands \[[@CR22]\]. The Medical Ethics Committee of the Erasmus Medical Centre Rotterdam approved the study, and written informed consent was obtained from all participants. From August 1990 until June 1993, a trained research assistant collected data on health, medication use, lifestyle, and risk indicators for chronic diseases during a home interview. Subjects were subsequently invited at the study centre for clinical examination and assessment of diet.

Assessment of diet {#Sec4}
------------------

Subjects were interviewed at the study centre by a trained dietician, who used a validated, semi-quantitative food frequency questionnaire \[[@CR23]\]. The intake of total energy, alcohol, macronutrients, and a large number of micronutrients was computed using Dutch food composition tables \[[@CR24]\]. No information on salt use was obtained and therefore data on dietary sodium were considered unreliable for this analysis.

Clinical examination {#Sec5}
--------------------

Height and body weight were measured with the subject wearing indoor clothing without shoes. The body mass index was computed as weight divided by height squared. A trained research assistant measured sitting systolic and diastolic blood pressure twice with a random-zero sphygmomanometer after a 5-min rest, and values were averaged. Hypertension was defined as a systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg or use of antihypertensive medication. Diabetes mellitus was considered present when the subject reported antidiabetic treatment, or when random or post-load plasma glucose levels were 11.1 mmol/l or higher. CVD was considered present in case of a verified history of myocardial infarction, stroke, coronary bypass grafting, or percutaneous transluminal coronary angioplasty. Serum total and HDL cholesterol level (mmol/l) were determined by standard laboratory methods \[[@CR25]\].

Assessment of sodium and potassium excretion {#Sec6}
--------------------------------------------

Participants collected an overnight urine sample before visiting the research centre and recorded collection times on the jar. They were not aware that samples would be used for estimation of electrolyte intake. At the research centre, volumes were recorded, urines were swirled and 100 ml samples were taken. Samples were stored in plastic tubes at −20°C for future laboratory determinations. Urinary sodium, potassium and creatinine determinations were performed by Vitros^®^ 250 (formerly Ektachem 250) Chemistry System (Johnson & Johnson, Ortho-Clinical Diagnostics Inc., Rochester, New York). Determination of electrolytes and creatinine were based on potentiometry and enzymatic conversion, respectively. Urinary sodium and potassium concentrations (mmol/l) were standardized to 24-h values using recorded collection times and urinary volumes (ml). In addition, urinary sodium/potassium ratio was computed.

Follow-up procedures {#Sec7}
--------------------

The present analysis is based on follow-up data collected from baseline (1990--1993) until 1 January 1998. Informed consent for collection of follow-up data was obtained from 7,802 participants (98%). Information on vital status was obtained at regular intervals from municipal population registries. General practitioners (GPs) used a computerized information system to record fatal and non-fatal events in the research area (covering 85% of the cohort). In the Netherlands, the GP forms the link to all specialized medical care and clinical events are unlikely to be missed by this follow-up procedure. Research physicians verified all information on incident events using GP records and hospital discharge letters. Events were coded independently by two physicians according to the *International Classification of Diseases, 10th revision* (ICD-10) \[[@CR26]\]. Coded events were reviewed by a medical expert in the field, whose judgment was considered definite in case of discrepancies.

Myocardial infarction comprised ICD-10 code I21 and stroke comprised ICD-10 codes I60-I67. Both fatal and non-fatal incident events were recorded. For the present study, only first events were considered. Events followed by death within 28 days were classified as fatal. CVD mortality comprised fatal myocardial infarction, fatal stroke, sudden cardiac death and other forms of fatal CVD (ICD-10 codes I20-I25, I46, I49, I50, I60-I67, I70-I74, and R96).

Study population {#Sec8}
----------------

Of 7,129 subjects who visited the research centre, 6,605 adequately performed a timed overnight urine collection for which collection times were recorded and volumes exceeded 150 ml. Of those, 5,531 had blood pressure readings and these subjects were eligible for the present analysis. We followed a case--cohort approach for efficiency reasons. Assessment of urinary sodium, potassium and creatinine excretion was performed in all subjects who died (*n *= 795, including 217 cardiovascular deaths), and in those who experienced a myocardial infarction (*n *= 206) or stroke (*n *= 181) during follow-up. A random sample of 1,500 control subjects was taken from the eligible cohort for assessment of electrolyte excretions. Urine samples could not be retrieved for 52 of these subjects, and data on urinary sodium, potassium and creatinine were thus obtained in 1,448 subjects. Dietary data were available for 1,205 subjects (83%) of the random sample, 518 subjects (65%) who died during follow-up, 157 subjects (72%) who died from CVD, 170 subjects (83%) with an incident myocardial infarction and 147 subjects (81%) with an incident stroke. Reasons for missing dietary data were participation in the pilot phase of the Rotterdam Study, low cognitive function, and logistic reasons, as described in more detail elsewhere \[[@CR23]\]. Of the random sub-cohort (*n* = 1,448), 783 subjects (54%) were free of CVD and hypertension at baseline.

Data analysis {#Sec9}
-------------

Pearson correlations were computed to examine inter-relationships between urinary and dietary measures of electrolyte intake and associations with total energy intake.

The association of urinary and dietary electrolytes with incident myocardial infarction, incident stroke, cardiovascular mortality and all-cause mortality was evaluated in a case--cohort design with standard Cox proportional-hazards models with modification of the standard errors based on robust variance estimates \[[@CR27], [@CR28]\]. We used the method according to Barlow in which the random cohort is weighted by the inverse of the sampling fraction from the source population. Members of the random cohort are included from baseline until failure or censoring, whereas cases outside the cohort are included at the time of their event. For the Cox models we used Proc MI and Proc MIanalyze, in conjunction with Proc Phreg (SAS 8.2).

Relative risks (RR) with 95% confidence intervals (95%-CI) were computed per 1 standard deviation increase in urinary sodium (mmol/24 h), urinary potassium (mmol/24 h) and dietary potassium intake (mg/day), and per 1 unit increase in urinary sodium/potassium ratio. Two-sided *P*-values below 0.05 were considered statistically significant. Adjustment was made for age, sex and, in urinary analyses, for 24-h urinary creatinine excretion (model 1). In a second analysis (model 2), additional adjustment was made for body mass index (kg/m^2^), smoking status (current, past, or never), diabetes mellitus (yes/no), use of diuretics (yes/no), and highest completed education (three categories). In a third analysis (model 3), dietary confounders were additionally adjusted for, i.e. daily intake of total energy (kJ), alcohol (g), calcium (g), and saturated fat (g). In the analysis for urinary sodium we additionally included urinary potassium in this model, and vice versa.

Analyses were repeated after exclusion of subjects with a history of CVD or hypertension to avoid biased risk estimates due to intentional dietary changes. Within this sub-cohort, a predefined stratified analysis of urinary sodium and urinary sodium/potassium ratio with cardiovascular and all-cause mortality was performed in subjects with a high body mass index (i.e., ≥25 kg/m^2^), using model 3.

Also in the sub-cohort free of CVD and hypertension, the distribution of 24-h urinary sodium excretion was divided into quartiles to be able to examine the relationship with all-cause mortality at extreme intakes. Quartiles of urinary sodium (cut-off levels: 66, 105 and 151 mmol/24 h) were entered categorically into the fully adjusted model (model 3), using the lower quartile as the reference.

Results {#Sec10}
=======

The study had a median follow-up of 5.5 years. Baseline characteristics of the study population are shown in Table [1](#Tab1){ref-type="table"}. Randomly selected controls (*n *= 1,448) were expectedly healthier at baseline than cases, as indicated by a lower prevalence of hypertension, diabetes, and CVD. Table 1Baseline characteristics of the study populationRandom sampleCasesIncident MIIncident strokeCVD mortalityAll-cause mortalityNo. of subjects1,448206181217795In random sample (%)31312829Age (year)69.2 (8.7)71.0 (8.0)74.0 (8.5)76.8 (8.4)76.9 (8.9)Men (%)4162455149Body mass index (kg/m^2^)26.4 (3.8)26.3 (3.4)26.0 (3.3)26.2 (3.8)25.7 (3.8)Smoking status (%)^a^    Current2329282326    Former4148424740    Never3623292935Alcohol use (%)8174807173Educational level (%)^a,b^    Low5861606566    Intermediate3231343028    High108656Serum cholesterol (mmol/l)    Total6.6 (1.2)6.3 (1.3)6.5 (1.2)6.6 (1.4)6.3 (1.3)    HDL1.4 (0.4)1.3 (0.4)1.3 (0.4)1.2 (0.4)1.3 (0.4)Blood pressure (mmHg)    Systolic140 (22)145 (23)149 (24)146 (25)145 (25)    Diastolic74 (11)74 (12)75 (13)73 (13)73 (14)Hypertension (%)^c^3744535547Diabetes mellitus (%)^d^1021222621History of CVD (%)^e^1735173928Values are means with standard deviations, or percentages; CVD, cardiovascular disease; MI, myocardial infarction^a^Values not always add up to 100% due to rounding^b^Highest achieved level of education; low, primary education, or less; intermediate, secondary general or vocational education; high, higher vocational education, university^c^Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg or use of antihypertensive medication^d^Plasma glucose ≥11.1 mmol/l or treated with oral antidiabetes medication or insulin^e^Verified history of cardiovascular disease, i.e. myocardial infarction, stroke, coronary bypass-grafting, or percutaneous transluminal coronary angioplasty

Baseline urinary excretions and dietary intakes are presented in Table [2](#Tab2){ref-type="table"}. In the random sample, 24-h urinary sodium excretion estimated from overnight urine collection was 117 mmol (i.e., 2.7 g/day, which corresponds to a NaCl intake of 6.8 g/day). Urinary potassium excretion was 45 mmol/24 h (1.8 g/day), which was half the amount estimated by food frequency questionnaire (3.6 g/day). The correlation between urinary and dietary potassium was 0.21 (*P* \< 0.001). Table 2Baseline urinary excretions and dietary intakes of Dutch men and women aged 55 years and over: The Rotterdam StudyRandom subcohortCasesIncident MIIncident strokeCVD mortalityAll-cause mortality*Urinary excretion*^a^Volume (l/24 h)1.4 (0.6)1.4 (0.6)1.4 (0.6)1.3 (0.6)1.3 (0.6)Sodium (mmol/24 h)117 (69)124 (68)115 (72)99 (61)107 (66)Potassium (mmol/24 h)45 (22)47 (22)45 (23)44 (24)44 (22)Sodium/potassium2.8 (1.5)2.7 (1.3)2.7 (1.3)2.5 (1.4)2.6 (1.6)Creatinine (mmol/24 h)9.2 (4.9)9.8 (4.7)8.4 (4.4)8.1 (4.7)8.1 (4.4)Sodium/creatinine13.8 (6.6)13.6 (6.1)14.6 (7.1)14.0 (8.0)14.8 (7.9)Potassium/creatinine5.4 (2.2)5.3 (2.1)5.8 (2.1)6.1 (2.6)6.1 (2.5)*Dietary intake*^b^Total energy (mJ/day)8.3 (2.1)8.6 (2.2)8.4 (2.2)8.3 (2.0)8.5 (2.2)Saturated fat (g/day)32 (12)34 (13)34 (13)33 (13)34 (12)Calcium (g/day)1.1 (0.4)1.1 (0.4)1.1 (0.4)1.1 (0.5)1.1 (0.4)Sodium (g/day)^c^2.2 (0.7)2.3 (0.6)2.2 (0.6)2.2 (0.7)2.2 (0.7)Potassium (g/day)3.6 (0.8)3.7 (0.8)3.6 (0.8)3.6 (0.9)3.6 (0.9)Values are means with standard deviations; CVD, cardiovascular disease; MI, myocardial infarction^a^Based on one timed overnight urine sample^b^Dietary data were available for 1,205 subjects of the random sample (83%), 170 MI cases (83%), 147 stroke cases (81%), 157 CVD deaths (72%), and 518 deaths from any cause (65%)^c^Only from foods, discretionary sources not included

RR for cardiovascular events and all-cause mortality per 1-SD increase in 24-h urinary sodium are presented in Table [3](#Tab3){ref-type="table"}. Urinary sodium was not significantly associated with incident myocardial infarction, incident stroke, or overall mortality. For CVD mortality, however, a borderline significant inverse association was observed (RR = 0.77 (0.60--1.01) per 1-SD, model 3) but the relationship was attenuated after excluding subjects with a history of CVD or hypertension (RR = 0.83 (0.47--1.44) per 1-SD, model 3). In subjects initially free of CVD, the risk of all-cause mortality was also examined across quartiles of 24-h urinary sodium (median values: 45, 87, 125 and 190 mmol, respectively). RR in consecutive quartiles, using the lower quartile as the reference, were 0.80 (0.43--1.49), 0.66 (0.34--1.27) and 0.98 (0.54--1.78), respectively (model 3). In a subgroup analysis of CVD free subjects with a body mass index ≥25 kg/m^2^, the association of urinary sodium with CVD mortality or all-cause mortality was neither statistically significant (RR = 0.91 (0.44--1.89) and RR = 1.19 (0.86--1.66) per 1-SD, respectively; model 3). Table 3Relative risk of urinary sodium with cardiovascular events and all-cause mortality in Dutch men and women aged 55 years and overAll subjects^a^Subjects initially free of CVD and hypertension^a^*Incident MI*RR, model 1^b^1.13 (0.95--1.34)1.04 (0.75--1.43)RR, model 2^c^1.16 (0.98--1.39)1.07 (0.77--1.50)RR, model 3^d^1.19 (0.97--1.46)1.14 (0.77--1.69)*Incident stroke*RR, model 11.09 (0.89--1.33)1.16 (0.84--1.61)RR, model 21.09 (0.87--1.35)1.15 (0.81--1.62)RR, model 31.08 (0.80--1.46)1.02 (0.66--1.58)*CVD mortality*^e^RR, model 10.74 (0.60--0.91)0.84 (0.59--1.22)RR, model 20.83 (0.68--1.02)0.95 (0.66--1.39)RR, model 30.77 (0.60--1.01)0.83 (0.47--1.44)*All-cause mortality*RR, model 10.90 (0.81--1.02)1.00 (0.83--1.20)RR, model 20.96 (0.84--1.09)1.10 (0.91--1.34)RR, model 30.95 (0.81--1.12)1.12 (0.86--1.46)RR, Relative risk with 95% confidence interval per standard deviation increase in urinary sodium (mmol/24 h), obtained by Cox proportional hazard analysis^a^Number of cases and subjects in random sample given in Table [1](#Tab1){ref-type="table"}^b^Ajusted for age, sex and (for urinary sodium) 24-h urinary creatinine excretion^c^As model 1, with additional adjustment for body mass index, smoking status, diabetes, use of diuretics, highest completed education^d^As model 2, with additional adjustment for daily intake of total energy, alcohol, calcium, saturated fat and 24-h urinary potassium excretion^e^Cardiovascular mortality comprises fatal myocardial infarction, fatal stroke, sudden cardiac death and other forms of fatal CVD

Findings for potassium are presented in Table [4](#Tab4){ref-type="table"}. Urinary potassium tended to be positively associated with incident CVD events or mortality, especially in subjects who were initially free of CVD and hypertension. After full adjustment for confounders (model 3), however, none of these associations were statistically significant. Urinary potassium did neither predict all-cause mortality. For dietary potassium, similar results were obtained except for risk of all-cause mortality that was significantly reduced both in the entire cohort (RR = 0.78 (0.65--0.94 per 1-SD) and in subjects initially free of CVD and hypertension (RR = 0.71 (0.51--1.00), model 3). Table 4Relationship of urinary and dietary potassium with cardiovascular events and all-cause mortality in Dutch men and women aged 55 years and overAll subjects^a^Subjects initially free of CVD and hypertension^a^Urinary excretion (mmol/24 h)Dietary intake (mg/day)Urinary excretion (mmol/24 h)Dietary intake (mg/day)*Incident MI*RR, model 1^b^1.10 (0.89--1.35)0.98 (0.85--1.13)1.15 (0.84--1.59)1.14 (0.85--1.54)RR, model 2^c^1.16 (0.94--1.43)0.94 (0.81--1.09)1.25 (0.94--1.74)1.07 (0.78--1.46)RR, model 3^d^1.11 (0.87--1.43)0.90 (0.65--1.24)1.22 (0.79--1.87)1.32 (0.65--2.67)*Incident stroke*RR, model 11.09 (0.87--1.36)0.99 (0.84--1.17)1.12 (0.79--1.60)1.07 (0.79--1.43)RR, model 21.12 (0.89--1.42)0.99 (0.84--1.16)1.15 (0.77--1.71)1.20 (0.86--1.68)RR, model 31.17 (0.86--1.58)1.02 (0.71--1.46)1.11 (0.61--2.04)1.06 (0.50--2.29)*CVD mortality*^e^RR, model 11.13 (0.90--1.41)0.97 (0.82--1.14)1.63 (1.14--2.33)1.23 (0.83--1.84)RR, model 21.14 (0.92--1.42)0.95 (0.81--1.12)1.66 (1.08--2.56)1.19 (0.78--1.83)RR, model 31.23 (0.94--1.60)0.97 (0.72--1.31)1.45 (0.84--2.54)1.43 (0.67--3.03)*All-cause mortality*RR, model 11.04 (0.91--1.18)0.91 (0.82--1.01)1.06 (0.88--1.28)0.95 (0.78--1.17)RR, model 21.06 (0.86--1.31)0.89 (0.80--0.99)1.06 (0.86--1.31)0.90 (0.73--1.12)RR, model 31.08 (0.91--1.28)0.78 (0.65--0.94)0.95 (0.71--1.26)0.71 (0.51--1.00)RR, Relative risk with 95% confidence interval per standard deviation increase in urinary or dietary potassium, obtained by Cox proportional hazard analysis^a^Number of cases and subjects in random sample given in Table [1](#Tab1){ref-type="table"}^b^Ajusted for age, sex and (for urinary potassium) 24-h urinary creatinine excretion^c^As model 1, with additional adjustment for body mass index, smoking status, diabetes, use of diuretics and highest completed education^d^As model 2, with additional adjustment for daily intake of total energy, alcohol, calcium, saturated fat and 24-h urinary sodium excretion^e^Cardiovascular mortality comprises fatal myocardial infarction, fatal stroke, sudden cardiac death and other forms of fatal CVD

Data for urinary sodium/potassium ratio (Table [5](#Tab5){ref-type="table"}) showed no relationship with CVD events and mortality. When restricting this analysis to CVD free subjects with a body mass index ≥25 kg/m^2^, urinary sodium/potassium ratio was significantly associated with all-cause mortality (RR = 1.19 (1.02--1.39) per unit, model 3), but not with CVD mortality (RR = 0.86 (0.60--1.25)). Table 5Relationship of urinary sodium/potassium ratio with cardiovascular events and all-cause mortality in Dutch men and women aged 55 years and overAll subjects^a^Subjects initially free of CVD and hypertension^a^*Incident MI*RR, model 1^b^1.03 (0.93--1.14)0.92 (0.76--1.13)RR, model 2^c^1.02 (0.92--1.13)0.90 (0.73--1.10)RR, model 3^d^1.04 (0.93--1.17)0.91 (0.72--1.16)*Incident stroke*RR, model 11.01 (0.89--1.13)1.01 (0.83--1.23)RR, model 20.99 (0.86--1.13)0.99 (0.77--1.20)RR, model 30.99 (0.83--1.18)0.90 (0.66--1.22)*CVD mortality*^e^RR, model 10.88 (0.77--1.01)0.85 (0.65--1.11)RR, model 20.93 (0.81--1.06)0.86 (0.66--1.13)RR, model 30.92 (0.80--1.07)0.91 (0.65--1.27)*All-cause mortality*RR, model 10.99 (0.91--1.06)1.04 (0.91--1.18)RR, model 20.99 (0.92--1.08)1.06 (0.93--1.22)RR, model 31.01 (0.91--1.12)1.13 (0.93--1.36)RR, Relative risk with 95% confidence interval per 1 unit increase in urinary sodium/potassium ratio, obtained by Cox proportional hazard analysis^a^Number of cases and subjects in random sample given in Table [1](#Tab1){ref-type="table"}^b^Adjusted for age, sex and 24-h urinary creatinine excretion^c^As model 1, with additional adjustment for body mass index, smoking status, diabetes, use of diuretics and highest completed education^d^As model 2, with additional adjustment for daily intake of total energy, alcohol, calcium, and saturated fat^e^Cardiovascular mortality comprises fatal myocardial infarction, fatal stroke, sudden cardiac death and other forms of fatal CVD

Discussion {#Sec11}
==========

In an unselected population of older Dutch subjects we found no consistent association of urinary sodium and potassium with CVD events or mortality. Dietary potassium estimated by food frequency questionnaire, however, was associated with a lower risk of all-cause mortality. Urinary sodium/potassium ratio was positively associated with mortality risk, but only in overweight subjects without CVD and hypertension at baseline.

Electrolyte intake was assessed from one overnight urine collection, which provides a crude estimate of short-term intake \[[@CR29], [@CR30]\]. Luft et al. examined the utility of nocturnal sodium excretion under controlled intake conditions, in which daily sodium intake was randomly varied \[[@CR31]\]. In that study, on a randomly selected day, both 24-h and nocturnal sodium excretion estimated the daily intake reasonably well. Nevertheless, it is likely that misclassification has attenuated the relationships with CVD events and mortality in our study. Incomplete urine collection was partly adjusted for by adding urinary creatinine excretion to the multivariate models. In addition, we examined the urinary sodium/potassium ratio, which is less influenced by incomplete urine collection. To exclude bias due to dietary changes, we repeated all analyses in a subgroup without CVD or hypertension at baseline.

Salt intake was not consistently related to CVD or mortality in our study. An explanation for the absence of a positive relationship, apart from regression dilution bias, may be the relatively narrow range of salt intake in the Netherlands and the lack of contrast in exposure within a single population. An increased risk of mortality was observed for high salt intake in overweight Finnish subjects with 24-h urinary excretions close to 200 mmol (RR = 1.56 per 100 mmol) \[[@CR16]\]. However, this could not be confirmed in our analysis of quartiles of sodium intake in relation to overall mortality (RR = 0.98 in CVD free subjects with median sodium excretion of 190 mmol/24 h). The absence of a relationship between salt intake and mortality in our study corroborates the findings from the large Scottish Heart Health Study among almost 12,000 middle-aged subjects with 24-h urine samples \[[@CR11]\]. Follow-up data of the MRFIT trial neither showed a relationship between dietary sodium intake estimated by 24-h recall and cardiovascular events or mortality \[[@CR12]\]. However, other prospective epidemiological studies do suggest that sodium intake is related to morbidity and mortality \[[@CR6], [@CR7], [@CR15], [@CR16]\], although this may be confined to specific subgroups with overweight, hypertension or high salt intake. In overweight subjects, we did find a positive relationship between urinary sodium/potassium ratio and overall mortality (19% increase in risk per unit change in sodium/potassium ratio).

A protective effect of potassium intake against stroke, as previously reported \[[@CR19]--[@CR21]\], could not be confirmed by our data. We neither observed an association between potassium intake and coronary events. Long-term rather than short-term intake may be relevant and therefore we estimated habitual potassium intake during the preceding year by food frequency questionnaire. Mortality risk was reduced by 29% per 1-SD increase in dietary potassium, although only in subjects initially free of CVD and hypertension. Except for misclassification, although less likely than for sodium, we have no explanation for the absent relationship between potassium intake and CVD events. In the Scottish Heart Health Study, 24-h urinary potassium excretion was inversely related to all-cause mortality and coronary events \[[@CR11]\]. Data on potassium intake in relation to mortality, however, are sparse and more prospective population-based studies are needed to draw conclusions. Preferably, the effect of dietary potassium on CVD should be examined in a randomized trial.

Prolonged differences in blood pressure of 5 mmHg may result in a one-third reduction in stroke and one-fifth reduction in coronary events \[[@CR32]\]. Meta-analysis of randomized controlled trials showed that sodium reduction around 2 g per day could lower blood pressure by 2--3 mmHg, with the effect being twice as large in hypertensives \[[@CR33]\]. The World Health Organization recommends that people should consume less than 5 g of salt (i.e. 2 g of sodium) per day in order to prevent CVD \[[@CR34]\]. From this and other epidemiological studies we conclude that effect of dietary salt on clinical cardiovascular endpoints and overall mortality within the range of intake commonly observed in Western countries has not yet been established. More research is needed to settle the discussion regarding this major public health issue.

This work was funded by the Dutch Kidney Foundation (Grant\# C99-1847).
